Open Nav

Hillstream BioPharma Inc.

  • Randy Milby, Hillstream BioPharma Inc.

Investor update

  • Date:Wednesday, October 17
  • Time:3:00 PM - 3:15 PM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Hillstream BioPharma is a development-stage company advancing improved therapies for patients with cancer. Our competitive advantage is to enhance the safety and efficacy of FDA-approved oncology therapies by encapsulating them in proprietary polymeric nanoparticles comprised of FDA-recognized inactive ingredients. Encapsulation ensures delivery within the tumor cells and prevents free drug levels in circulation that can cause toxicity. The slow and sustained release of the therapy may also reduce the frequency of dosing while maintaining its efficacy. The novel formulation allows us to build a strong patent estate and seek FDA Orphan Drug Designation in specific indications. Our proprietary formulations of bortezomib and oxaliplatin are currently in preclinical development for cancers with significant unmet need. By taking advantage of the FDA’s 505(b)(2) regulatory pathway, we could expedite the development process and bring these novel formulations to market to offer patients hope.
  • Company
  • Company HQ City:Chester
  • Company HQ Country:United States
  • Company HQ State:New Jersey                 
  • CEO/Top Company Official:Randy Milby
  • Year Founded:2017
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :HSB-407
  • Development Phase of Primary Product:Pre-Clinical
  • Total Amount Raised to Date, In All Rounds:<$1M
Randy Milby
Hillstream BioPharma Inc.